Biochemical parameters of blood in different grades of bladder cancer

D. Vasilyuk, V. Dmytryk, T. Luhovska, P. Yakovlev
ESC "Institute of Biology and Medicine", Taras Shevchenko National University of Kyiv; ESC "Institute of Biology and Medicine", Taras Shevchenko National University of Kyiv; ESC "Institute of Biology and Medicine", Taras Shevchenko National University of Kyiv; O. Bogomolets National Medical University, Kyiv

Abstract


The frequency of diagnosed cancer is increasing. Bladder cancer (BC) is the 7th most frequent case of oncological diseases among men, and
17th among women all around the world. BC is more common in developed countries, in the western world there are the 4th most frequent cases
among man and the 9th among women. This disease is characterized by a high mortality rate. There is a lack of diagnostic methods in comparison
with other urological oncological diseases. Important diagnostic studies depending on the histopathological gradation. Malignant cells are
characterized by high proliferative capacity, which is provided by inflammatory molecules, such as IL-1β and IL-6. In parallel with chronic
inflammatory processes, increased vascular permeability can lead to a change in the concentration of toxins, metabolites, and products of tissue
disintegration in tumors. During malignant diseases, significant changes in the microcirculation system can occur, as a result of which there is a
disruption in the functions of the lymphatic system, metabolic disturbances and as result – changes in biochemical parameters of the blood. A
general clinical blood test, especially the number of leukocytes, indicates a significant response of cellular immunity in cancer patients. The
slightest deviations in the hematological parameters may indicate the progression of cancer. In our study of the biochemical parameters of the
blood of patients with BC, the dependence of the parameters of the general clinical analysis and certain biochemical blood tests on the BC stage on
histopathological gradation is traced. Determination of the investigated parameters in blood in patients with BC revealed an increase in the content
of pro-inflammatory cytokines, the vascular endothelial growth factor, urea, creatinine, the number of leukocytes and neutrophils. Also, we showed
a decrease in the number of erythrocytes, monocytes, lymphocytes, and eosinophils in dependence on histopathological graduation.


Keywords


bladder cancer, IL-1β, IL-6, VEGF,complete blood count, biochemical parameters,histopathological graduation

Full Text:

PDF>PDF

References


Agnelii G. Venous thromboembolism and cancer: two-way clinicalassociation. Agnelii G, et al. Thromb. Haemost. 1997;78, N 1:117–120.

Bajou K., Noel A., Gerard R., et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion andvascularization. Nat Med. 1998;4:923-928.

Becker M., Tilki D., Szarvas T., Rubben H., Ergun S. Urine based markers of angiogenesis in bladder cancer. Urologe A.2009;48:609-614. 4. Berger D. Plasmin/plasminogen system in colorectal cancer. World J Surg. 2002;26:767-771.

Cicco M. The prothrombotic state in cancer: pathogenic mechanisms. Crit. Rev. Oncol. Hematol. 2004; 50.3:187–196.

Duffy M., Maguire T., Mc Dermott E., O'Higgins N. Urokinase plasminogen activator: a prognostic marker inmultiple types of cancer. J Surg Oncol. 1999;71:130-135.

Ghezzi L., et al. Prognostic significance of preoperative plasma fibrinogen in endometrial cancer. Gynecol. Oncol. 2010;119: 309–313.

Gontero P., Banisadr S., Frea B., Brausi M. Metastasismarkers in bladder cancer: a review of the literature andclinical considerations. Eur Urol. 2004;46:296-311.

Harbeck N., Kates R., Gauger K., et al. Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer. Thromb Haemost. 2004;91:450-456.

Ikushima, S., Ono R., Fukuda K., et al. Trousseau's syndrome: cancer-associated thrombosis. Jpn. J. Clin. Oncol. 2016; 46: 204–208.

Ishchuk T., Glavachek D., Savchuk O., Yakovlev P., Falaleeva T., Beregova T., Ostapchenko L. (2018). Plasma levels of MMPs and TIMP-1 in urinary bladder cancer patients. Biomedical Research and Therapy. 5. 1931-1940. 10.15419/bmrat.v5i1.407.

Jones J., et al. Plasma fibrinogen and serum C-reactive protein are associated with non-small cell lung cancer. Lung Cancer. 2006; 53:97–101

Kakkar, A., Levine M. Thrombosis and cancer: implications beyond Trousseau. Journal of Thrombosis and Haemostasis. 2004; 8: 1261–1262.

Kwaan H., Wang J., Svoboda K., Declerck P. Plasminogenactivator inhibitor 1 may promote tumour growth throughinhibition of apoptosis. Br J Cancer. 2000;82:1702-1708.

Lademann U., Romer M. Regulation of programmed celldeath by plasminogen activator inhibitor type 1 (PAI-1).Thromb Haemost. 2008;100:1041-1046.

Lee J., et al. Preoperative plasma fibrinogen levels in gastric cancer patients correlate with extent of tumour. Hepatogastroenterology. 2004; 51: 1860–1863

Lima, L., Monteiro R.. 2013. Activation of blood coagulation in cancer: implications for tumour progression.Biosci.Rep.33. https://doi.org/10.1042/BSR20130057

Loreto M., Martinis D., Corsi M. Coagulation and cancer:implications for diagnosis and management. Pathol. Oncol. Res.2000; 6:302–312.

Mackman N., Tilley R., Key N. Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. Arterioscler. Thromb. Vasc. 2007. Biol. 27: 1687-1693.

Palmieri D., Lee J., Juliano R., Church F. Plasminogenactivator inhibitor-1 and -3 increase cell adhesion and motility of MDA-MB-435 B breast cancer cells. J Biol Chem.2002;277:40950-40957

Palta, S., Saroa R., Palta A. 2014. Overview of the coagulation system. Indian J. Anaesth. 58: 515–523.

Palumbo J., et al. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood. 2000; 96:3302–3309.

Prandoni P., Piccioli A., Girolami A. Cancer and venous thromboembolism: an overview. Hematologica. 1999; 84: 437–445.

Raetska Ya., Chornenka N., Koval Т., Savchuk О., Beregova Т., Ostapchenko L. Cytokine profile indicators in rat blood serum in a model of esophagus burn induced by antioxidant chemical preparation. Biomedical Research and Therapy. 2017. 4. 1591. 10.15419/bmrat. v4i9.367.

Repetto L., Ombretta D. Coagulation and fibrinolysis in gastric cancer. Annals of the New York Academy of Sciences. 2017.1404.10.1111/nyas.13454.

Rice K., Brassell S., Mc Leod D. Venous thromboembolism in urologic surgery: prophylaxis, diagnosis, and treatment //Reviews in urology. – 2010. – V.12. – P.111-24.

Rijken D. Plasminogen activators and plasminogen activator inhibitors: biochemical aspects. Baillieres Clin Haematol. 1995 ;8:291-312.

Schmitt M., Harbeck N., Thomssen C., et al. Clinical impactof the plasminogen activation system in tumor invasion andmetastasis: prognostic relevance and target for therapy.Thromb Haemost. 1997;78:285-296.

Seebacher V., et al. The prognostic value of pasma fibrinogen levels in patients with endometrial cancer: a multi-centre trial. BritishJournalofCancer. 2010; 102: 952–956.

Shariat S., Monoski M., Andrews B., et al: Association of plasma urokinase-type plasmino gen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder. Urology. 2003; 61: 1053-1058.

Span P., Witjes J., Grebenchtchikov N., et al. Components of the plasminogen activator system and their complexes in renal cell and bladder cancer: comparison betweennormal and matched cancerous tissues. BJU Int.2008; 102: 177-182.

Stahl A., Mueller B. Melanoma cell migration on vitronectin: regulation by components of the plasminogen activationsystem. Int J Cancer. 1997;71:116-122.

Von Tempelhoff G., et al. Association between blood rheology, thrombosis and cancer survival in patients with gynecologic malignancy. Clin. Hemorheol. Microcirc. 2000; 22:107–130.

Received in the editorial: 10.09.2018

Received revised version: 8.10.2018

Signed for press: 8.10.2018


Refbacks

  • There are currently no refbacks.


Лицензия Creative Commons
This journal is available according to the Creative Commons License «Attribution» («Атрибуція») 4.0 Global (CC-BY).